Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
LinusBio logo — Precision Exposome Medicine

LinusBio

Precision Exposome Medicine

Founded 2020 United States North Brunswick, United States 35 employees Total: $47.65M Biotechnology, Health Care +1

General Information

Company Name LinusBio
Founded Year 2020
Location United States North Brunswick, United States
Employees 35
Industries Biotechnology, Health Care, Pharmaceutical
Business Model B2B, D2C, B2D
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with LinusBio. To contact LinusBio, visit linusbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does LinusBio compare?

A PDF of LinusBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting LinusBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About LinusBio

LinusBio, founded in 2020, is a pioneering company operating at the forefront of Precision Exposome Medicine. Revolving around breakthrough science, the company focuses on patient-centric solutions within the biotechnology, health care, and pharmaceutical industries. Its innovative program pipeline is actively advancing the discovery of precision exposome medicine biomarkers and targets many diseases, including CNS disorders like autism spectrum disorder and amyotrophic lateral sclerosis, as well as illnesses in gastroenterology, renal disease, and oncology.

Headquartered in the United States, LinusBio represents a new frontier in medical practice by addressing historically challenging domains with no available molecular endpoints. Recently, the company secured a $6.15M in a Late VC investment dated 01 August 2024, signifying strong confidence from the investment community in its disruptive potential.

Business keywords: Precision Exposome Medicine, Biomarkers, Target Discovery, CNS Disorders, Autism Spectrum Disorder, Amyotrophic Lateral Sclerosis, Inflammatory Bowel Disease, Renal Disease, Oncology, Genomic Diseases, Genomic Sequencing Analysis, Technology Platform, Precision Medicine, Patient-Centric Healthcare, Breakthrough Science

Services & Products

Precision exposome biomarker development
Early diagnosis technology
AI-powered data analysis
Non-invasive diagnostic tests

Target Customers

Healthcare providers Families of children with developmental disorders Biotechnology researchers Clinical experts Pharmaceutical companies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC $6.15M -
01 Aug 2024
Series A $8.00M 2
Bow Capital
Bow Capital, David Bellet Family Office
01 Jun 2023
Series A $16.00M 5
GreatPoint Ventures Bow Capital Divergent Investments
GreatPoint Ventures, Bow Capital +3
01 Jan 2023
Early VC $17.50M -
01 Mar 2022
Spinout Undisclosed -
01 Jan 2021

LinusBio Alternatives & Competitors

View All Alternatives
LinusBio vs
Nextera AS
Nextera AS Norway

Opening a new arena for drug discovery

Seed
20 employees
Biotechnology, Health Care
Compare LinusBio vs Nextera AS
LinusBio vs
Celadon Pharmaceuticals
Celadon Pharmaceuticals United Kingdom

UK-based pharmaceutical company focused on R&D, cultivation, production and sale of cannabis-based m...

IPO
18 employees
Biopharma, Biotechnology
Compare LinusBio vs Celadon Pharmaceuticals
LinusBio vs
Brainify.AI
Brainify.AI United States

AI biomarker platform for a novel treatment developed for depression. Part of J&J Jlabs and Merck DS...

Pre-Seed
11 employees
AI, Health Care
View all alternatives

FAQ About LinusBio

Precision Exposome Medicine
LinusBio was founded in 2020.
LinusBio is headquartered in North Brunswick, United States.
LinusBio operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Precision Exposome Medicine, Biomarkers, Target Discovery and CNS Disorders. Its customers include Healthcare providers, Families of children with developmental disorders and Biotechnology researchers.
LinusBio has a B2B, D2C and B2D business model. Its revenue comes from Product Sales, Service Fee and Licensing.
LinusBio has approximately 35 employees.
LinusBio has completed 5 funding rounds, raising a total of $47.65M.
LinusBio offers: Precision exposome biomarker development, Early diagnosis technology, AI-powered data analysis, Non-invasive diagnostic tests.
Top alternatives and competitors to LinusBio include Nextera AS, Celadon Pharmaceuticals, Brainify.AI, Anatolia Geneworks, ProMIS™ Neurosciences, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
LinusBio and Nextera AS are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for LinusBio, https://bouncewatch.com/company/linusbio, updated 4 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout